Adaptive Biotechnologies Corporation $ADPT Shares Sold by Royal Bank of Canada

Royal Bank of Canada lowered its stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) by 40.9% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 46,470 shares of the company’s stock after selling 32,205 shares during the period. Royal Bank of Canada’s holdings in Adaptive Biotechnologies were worth $645,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd acquired a new position in Adaptive Biotechnologies during the fourth quarter valued at $28,000. EverSource Wealth Advisors LLC grew its position in Adaptive Biotechnologies by 197.1% during the 4th quarter. EverSource Wealth Advisors LLC now owns 2,359 shares of the company’s stock worth $38,000 after purchasing an additional 1,565 shares during the period. Assetmark Inc. grew its position in Adaptive Biotechnologies by 867.9% during the 4th quarter. Assetmark Inc. now owns 3,020 shares of the company’s stock worth $49,000 after purchasing an additional 2,708 shares during the period. T. Rowe Price Investment Management Inc. purchased a new position in shares of Adaptive Biotechnologies during the 4th quarter valued at about $51,000. Finally, Strive Financial Group LLC acquired a new position in shares of Adaptive Biotechnologies in the 4th quarter valued at about $52,000. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Insider Buying and Selling at Adaptive Biotechnologies

In related news, insider Harlan S. Robins sold 492,400 shares of the company’s stock in a transaction that occurred on Tuesday, July 21st. The stock was sold at an average price of $21.89, for a total value of $10,778,636.00. Following the completion of the transaction, the insider directly owned 812,058 shares of the company’s stock, valued at $17,775,949.62. This represents a 37.75% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Robert Hershberg sold 30,664 shares of the stock in a transaction that occurred on Tuesday, August 18th. The shares were sold at an average price of $24.40, for a total transaction of $748,201.60. Following the completion of the transaction, the director owned 46,683 shares in the company, valued at $1,139,065.20. This represents a 39.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 2,062,325 shares of company stock worth $46,659,069. 5.70% of the stock is currently owned by corporate insiders.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ ADPT opened at $25.99 on Monday. Adaptive Biotechnologies Corporation has a 52 week low of $12.00 and a 52 week high of $26.16. The stock has a market capitalization of $4.15 billion, a price-to-earnings ratio of -63.39 and a beta of 2.08. The company has a quick ratio of 4.68, a current ratio of 4.79 and a debt-to-equity ratio of 2.22. The firm has a 50-day simple moving average of $22.06 and a 200-day simple moving average of $17.34.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.12). The company had revenue of $71.55 million during the quarter, compared to analyst estimates of $65.44 million. Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%.The business’s revenue was up 21.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.17) earnings per share. On average, equities analysts predict that Adaptive Biotechnologies Corporation will post -0.4 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ADPT has been the subject of several recent research reports. TD Cowen lifted their price target on Adaptive Biotechnologies from $25.00 to $28.00 and gave the company a “buy” rating in a research report on Thursday, July 30th. Piper Sandler raised their price target on shares of Adaptive Biotechnologies from $20.00 to $27.50 and gave the company an “overweight” rating in a research report on Tuesday, August 4th. Guggenheim upped their price objective on shares of Adaptive Biotechnologies from $22.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Finally, BTIG Research lifted their price target on Adaptive Biotechnologies from $24.00 to $25.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Five analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.42.

About Adaptive Biotechnologies

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.